Molecular subtype analysis determines the association of advanced breast cancer in Egypt with favorable biology

BMC Women's Health

Volumn 11, Issue , 2011, Pages

  Salhia, Bodour ^a   Tapia, Coya ^b,c   Ishak, Elia A ^d   Gaber, Salwa ^e   Berghuis, Bree ^f   Hussain, Khateeb H ^a   DuQuette, Rachelle A ^a   Resau, James ^f   Carpten, John ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d CAIRO UNIVERSITY   (Egypt)

^e Minia University   (Egypt)

^f VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Africa; Breast cancer subtypes; Early detection; Egypt; Ethnicity

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; EARLY DIAGNOSIS; EGYPT; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREVALENCE; PROGNOSIS; BREAST TUMOR; CANCER STAGING; ETHNOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; BREAST NEOPLASMS; EARLY DIAGNOSIS; EGYPT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS;

EID: 80053353741     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-11-44     Document Type: Article

References (27)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer
2. Dey S, Soliman AS, Hablas A, Seifeldein IA, Ismail K, Ramadan M, El-Hamzawy H, Wilson ML, Banerjee M, Boffetta P, et al. Urban-rural differences in breast cancer incidence in Egypt (1999-2006). Breast
3. Zanetti R, Tazi MA, Rosso S. New data tells us more about cancer incidence in North Africa. Eur J Cancer 46(3):462-466.
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752. 10.1038/35021093, 10963602.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
6. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100(14):8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
7. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750. 10.1093/jnci/djp082, 2684553, 19436038.
8. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-2502. 10.1001/jama.295.21.2492, 16757721.
9. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
10. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010, 16(24):6100-6110. 10.1158/1078-0432.CCR-10-1533, 21169259.
11. Genestie C, Zafrani B, Asselain B, Fourquet A, Rozan S, Validire P, Vincent-Salomon A, Sastre-Garau X. Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems. Anticancer Res 1998, 18(1B):571-576.
12. Paik S, Taniyama Y, Geyer CE. Anthracyclines in the treatment of HER2-negative breast cancer. J Natl Cancer Inst 2008, 100(1):2-4. 10.1093/jnci/djm277, 18159066.
13. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008, 358(13):1409-1411. 10.1056/NEJMc0801440, 18367751.
14. Dey S, Soliman AS, Hablas A, Seifeldin IA, Ismail K, Ramadan M, El-Hamzawy H, Wilson ML, Banerjee M, Boffetta P, et al. Urban-rural differences in breast cancer incidence by hormone receptor status across 6 years in Egypt. Breast Cancer Res Treat 120(1):149-160.
15. Anderson BO. Breast cancer hormone receptor status in Egypt: are we asking the questions that matter most?. Breast Cancer Res Treat 120(1):161-163.
16. Ben Abdelkrim S, Trabelsi A, Missaoui N, Beizig N, Bdioui A, Anjorin A, Jomaa W, Mokni M. Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: a study of 194 patients. Pathol Res Pract 2010, 206(11):772-775. 10.1016/j.prp.2010.07.012, 20850937.
17. Awadelkarim KD, Arizzi C, Elamin EO, Hamad HM, De Blasio P, Mekki SO, Osman I, Biunno I, Elwali NE, Mariani-Costantini R, et al. Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa. Histopathology 2008, 52(4):445-456. 10.1111/j.1365-2559.2008.02966.x, 18315597.
18. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7(1-2):4-13. 10.3121/cmr.2009.825, 2705275, 19574486.
19. Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009, 27(27):4515-4521. 10.1200/JCO.2008.19.6873, 2754904, 19704069.
20. Al Tamimi DM, Shawarby MA, Ahmed A, Hassan AK, AlOdaini AA. Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study. BMC Cancer 10:223.
21. Seedhom A, Kamal N. Factors Affecting Survival of Women Diagnosed with Breast Cancer in El-Minia Governorate, Egypt. International journal of preventatative medicine 2011, 2(3):113-138.
22. Lucotte G, Mercier G. Brief communication: Y-chromosome haplotypes in Egypt. Am J Phys Anthropol 2003, 121(1):63-66. 10.1002/ajpa.10190, 12687584.
23. Luis JR, Rowold DJ, Regueiro M, Caeiro B, Cinnioglu C, Roseman C, Underhill PA, Cavalli-Sforza LL, Herrera RJ. The Levant versus the Horn of Africa: evidence for bidirectional corridors of human migrations. Am J Hum Genet 2004, 74(3):532-544. 10.1086/382286, 1182266, 14973781.
24. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra JM, Jacquemier J, et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 2011, 126(2):407-420. 10.1007/s10549-010-0897-9, 20490655.
25. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, Adelaide J, Debono S, Houvenaeghel G, Maraninchi D, Viens P, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006, 66(9):4636-4644. 10.1158/0008-5472.CAN-06-0031, 16651414.
26. Lubinski J, Gorski B, Huzarski T, Byrski T, Gronwald J, Serrano-Fernandez P, Domagala W, Chosia M, Ucinski M, Grzybowska E, et al. BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 2006, 99(1):71-76. 10.1007/s10549-006-9182-3, 16541315.
27. Yin D, Morris C, Allen M, Cress R, Bates J, Liu L. Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups?. Cancer Causes Control 2010, 21(10):1721-1730. 10.1007/s10552-010-9601-y, 2941051, 20567897.